For your right to be curious.

Donate

Play Live Radio

Next Up:

0:00

0:00 0:00

Available On Air Stations

Join the NPR Illinois team!

Community Voices is seeking a co-host/editor to join Jeff Williams and Randy Eccles in getting to know our neighbors and more. Apply by May 25, 5 p.m.

The news department is seeking part-time fill-in anchor/reporters who are available either weekdays from 5:30 to 9 a.m. and/or 3:30 to 6 p.m. Apply by June 5, 5 p.m.

Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

NPR | By Sydney Lupkin,

Steve Inskeep

Published May 22, 2026 at 3:44 AM CDT

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

See stories by Sydney Lupkin

Steve Inskeep

Steve Inskeep is a host of NPR's Morning Edition, as well as NPR's morning news podcast Up First.

See stories by Steve Inskeep